Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX
Recorded on December 11, 2018
Join Drs. Naveen Pemmaraju and Ken Miller as they discuss
the diagnosis, treatment, and management of blastic plasmacytoid dendritic cell
neoplasm (BPDCN), an often misdiagnosed and highly aggressive hematologic
malignancy. Dr. Pemmaraju is a hematologist/oncologist at MD Anderson Cancer
Center in Houston, TX. On this episode, Dr. Pemmaraju discusses the origin of
BPDCN, methods of diagnosing and treating this rare disease, and the progress being
made in the field.
BPDCN Drug Updates: On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ELZONRIS™ (tagraxofusp) — the first treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older. For additional drug information, please visit: www.LLS.org/Drugs.
Naveen Pemmaraju, MD
Department of Leukemia
MD Anderson Cancer Center